PAR - The Billion Dollar Timeline, page-13

In any other case i would 100% agree with you, the extra promotion of a dual listing is a big advantage for sure. In our case word of mouth and press are going to be massive. Word will spread like wildfire and once the American press start headlining that there is a an alternative to nasty opioids and steroids in the war on joint pain...well...

As someone else (or others) have mentioned, supply might become an issue but hopefully Bene have some robust plans..they'll get some notice though..ie ramp up will be slower initially in my opinion until word really spreads.